+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

NASH and NAFLD, An Issue of Clinics in Liver Disease. The Clinics: Internal Medicine Volume 22-1

  • Book

  • January 2018
  • Elsevier Health Science
  • ID: 4414285

Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Clinics in Liver Disease

NASH and NAFLD

Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic

Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View

Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics

The Genetics of Pediatric Nonalcoholic Fatty Liver Disease

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography

Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom

The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

The Role of Nonalcoholic Fatty Liver Disease on Cardiovascular Manifestations and Outcomes

Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation

Authors

David Bernstein Head, Liver Sub-Specialty Service Line, Vice Chair of Medicine for Clinical Trials, Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Professor of Medicine and Educational Sciences, Zucker School of Medicine at Hofstra/NorthwellHofstra Northwell School of Medicine, Manhasset, NY.